INTERNATIONAL SPEAKERS

 

 

 

 

 

 

Prof. Dr. med. Dr. h.c. Michael Strupp, FANA, FEAN

Medical Faculty of Ludwig-Maximilians-Universität (LMU) München, Campus Grosshadern

Michael Strupp served as a Faculty Member of the Neuro-Ophthalmology & Neuro-Otology Section in the Neurological Disorders Faculty from 14 November 2005, and was appointed Section Head of the Neuro-Ophthalmology & Neuro-Otology Section on 7 February 2013.

His particular area of interest is the therapy of vestibular, ocular motor and cerebellar disorders. Some of his major achievements are: First, demonstration of the effectiveness of vestibular exercises in acute vestibular neuritis in a controlled clinical trial. Second, the benefit of steroids in acute vestibular neuritis, a placebo-controlled, four-arm trial published in the NEJM. Third, introduction of three new therapeutic principles: aminopyridines, as potassium channel blockers, for the treatment of downbeat, upbeat and central positioning nystagmus as well as episodic ataxia type 2; chlorzoxazone for the therapy of downbeat nystagmus; and, more recently, acetyl-DL-leucine for the treatment of ataxias and Niemann-Pick Type C. Fourth, the development of new light and practical examination glasses for nystagmus: the “M glasses”. Currently he is the principal investigator of six ongoing clinical trials. He is very much engaged in the “International Classification of Vestibular Disorders”, leading two of the groups.

He has authored 342 pubmed listed papers and five books on vertigo, dizziness and ocular motor disorders. He is currently Editor-in-Chief of Frontiers in Neuro-otology, Joint Chief Editor of the Journal of Neurology and a Member of the Editorial Board of Neurology. He has received many clinical and scientific awards, including the Hallpike-Nylen Award 2106, is a very passionate teacher and was awarded ‘Best Teacher’ by the German Neurological Society.

IMPORTANT PUBLICATION :

  • Adrion C, Fischer CS, Wagner J, Gurkov R, Mansmann U, Strupp M (2016) Efficacy and safety of betahistine treatment in patients with Meniere’s disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ 352:h6816
  • Bremova T, Malinova V, Amraoui Y, Mengel E, Reinke J, Kolnikova M, Strupp M (2015) Acetyl-dl-leucine in Niemann-Pick type C: A case series. Neurology 85:1368-1375
  • Claassen J, … Strupp M (2013) A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus – effects on slowphase eye velocity, postural stability, locomotion and symptoms. JNNP 84:1392-1399
  • Feil K, Claassen J, Bardins S, Teufel J, Krafczyk S, Schneider E, Schniepp R, Jahn K, Kalla R, Strupp M (2013) Effect of chlorzoxazone in patients with downbeat nystagmus: a pilot-trial. Neurology 81:1152-1158
  • Hüfner K Barresi D, Glaser M, Linn J, Adrion C, Mansmann U, Brandt T Strupp M (2008) Vestibular paroxysmia – diagnostic features and medical treatment. Neurology 71:1006-1014
  • Kalla R, Glasauer S, Büttner U, Brandt T, Strupp M (2007) 4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain 130:2441-2451

NATIONAL SPEAKERS

Leave a Reply

Close Menu